Testing effectiveness (Phase 2)Not Yet RecruitingNCT07161193
What this trial is testing
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Who this might be right for
Autoimmune Diseases
Hebei Senlang Biotechnology Inc., Ltd. 30